Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind

Commercialization to begin in the United States immediately. US-Ireland Pharmaceutical company expands its oral oncology pipeline.

Shorla Oncology (‘Shorla’), a US-Ireland specialty pharmaceutical company, and Therakind Ltd (‘Therakind’), a UK-based specialty pharmaceutical company have entered into an agreement under which Shorla has agreed to acquire Jylamvo, an oncology and autoimmune drug, for the US market. The therapy has been approved by the US Food and Drug Administration (FDA).

Jylamvo is an easy-to-administer, sweet tasting oral methotrexate solution that eliminates the need for crushing or splitting pills, or compounding into a liquid formulation. A drug that has recently suffered shortages in other dosages forms, Jylamvo is an alternative solution offering advantages over similar drugs because it remains stable at room temperature and does not require cold chain storage. It was approved by the US FDA in 2022 and is used to treat adults with acute lymphoblastic leukemia, mycosis fungoides, relapsed or refractory non-Hodgkin lymphoma, rheumatoid arthritis and severe psoriasis.

“We are delighted to acquire Jylamvo to provide an alternative solution for patients who may have difficulty swallowing pills,” said Sharon Cunningham, chief executive officer of Shorla Oncology. “This is another key step as Shorla grows and commercializes a portfolio of late-stage assets and improves efficiencies by providing more convenient and patient friendly formulations.”

The news comes shortly after Shorla announced that it has raised $35 million in Series B funding to accelerate the growth of its oncology portfolio by bringing therapies to market that will address drug shortages, and improve the preparation and application of oncology medication. This marks Shorla’s second US FDA approved product in its oncology portfolio.

“Therakind is pleased that Jylamvo will now become available to patients in the United States providing a palatable oral liquid alternative to treat a range of indications,” said Susan Conroy, chief executive officer of Therakind.

“This acquisition will provide a much-needed treatment to patients in need,” said Orlaith Ryan, chief technical officer and co-founder of Shorla Oncology. “It brings a crucial oral treatment to a larger patient population who suffer from cancer and other debilitating illnesses.”


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

he Intracept system, a basivertebral nerve ablation therapy, will be an addition to the Boston Scientific chronic pain portfolio that includes spinal cord stimulation, radiofrequency ablation and an interspinous spacer procedure.
"As Probo Medical has grown, we've seen the value of tailoring our commercial offering to the specific needs of specialists that we serve. Davis Medical provides us with exactly that in the cardiology specialty, with decades of experience and a refined approach to support cardiology practices with the equipment, services and supplies they need to run their practice," said Michael Asmer, CEO of Probo. "Additionally, the Davis Medical team adds significant strength to our footprint in the western US."
Paragon Medical serves a wide range of specialty applications including orthopedics, minimally invasive surgery, robotic surgery, and drug delivery. Paragon's product portfolio includes single-use and consumable surgical instruments and implantable components sold to a diverse blue-chip customer base of leading medical device manufacturers.
“Time is of the essence during medical emergencies, as we saw in 2022 when EU member states required emergency shipments of Tecovirimat SIGA to treat patients infected with mpox,” said Meridian Medical Technologgies Commercial Head – Injectables & Health Security, Tom Handel. “This joint procurement framework contract, a significant milestone for both Meridian and HERA, reduces the time and effort required to put individual contracts in place with each member state from months to days. There are now multiple paths in Europe for streamlined procurement, allowing member state agencies to get much needed medical countermeasures into the hands of those in need.”
Founded in 1969 and based in Fraser, Michigan, Healthmark Industries is a leading manufacturer, marketer, and distributor of consumable medical devices and supplies used by sterile processing departments in hospitals for cleaning verification and sterile instrument packaging. In its fiscal year ending October 31, 2023, Healthmark expects revenue to increase 15% to $126 million.

By using this website you agree to accept Medical Device News Magazine Privacy Policy